Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 July 1998

Placebo-controlled trial of l-arginine in the treatment of peripheral arterial obstructive disease patients

Maciej Sławński, Lidia Grodzińska, Elżbieta Kostka-Trąbka, Krzysztof Bieroń, Aleksandra Goszcz, Robert Jachym, Ryszard Korbut

Med Sci Monit 1998; 4(4): CR640-645 :: ID: 502128

Abstract

20 patients with peripheral arterial obstructive disease (PAOD) participated in a blind placebo controlled study. They received infusions of saline (placebo) for seven consecutive days and for the next seven days, 60 mmol of L-arginine (L-ARG) intravenously. Following this i. v. therapy, they were treated with tablets of L-ARG at a dose of 1 g, 3 times per day for 21 days. After seven days of placebo treatment, an improvement in exercise tests, a rise in the ankle/arm pressure ratio (AAPR), and an increase of blood flow in both calves (claudicant and non-claudicant) were observed. However, these effects were much more significant following L-ARG infusions. Placebo did not affect platelet susceptibility and fibrinolysis in a significant manner. L-ARG infusions inhibited spontaneous ADP and collagen induced platelet aggregation and stimulated fibrinolysis. L-ARG caused a significant increase in cGMP blood concentration levels while saline had no such effect. Clinical effects were more intensive following a 3 weeks oral therapy with L-ARG, but the influence on platelet aggregability, fibrinolysis and cGMP did not appear to be stronger. Our results suggest that i.v. therapy followed by orally administered L-ARG may serve in the prevention and therapy of PAOD patients. These findings call for further controlled studies on a greater number of patients.

Keywords: peripheral arterial obstructive disease, treatment, L-arginine, Nitric Oxide, cGMP levels, platelet aggregability, Fibrinolysis

Add Comment 0 Comments

Editorial

01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Review article  

Biomarkers for Early Prediction and Management of Preeclampsia: A Comprehensive Review

Med Sci Monit In Press; DOI: 10.12659/MSM.944104  

0:00

Clinical Research  

Lipid Peroxidation, Reduced Glutathione, and Glutathione Peroxidase Levels in Intervertebral Discs of Patie...

Med Sci Monit In Press; DOI: 10.12659/MSM.944335  

Clinical Research  

Enhanced Recovery of Local Anesthesia in Pediatric Patients: The Impact of Photobiomodulation on Reversing ...

Med Sci Monit In Press; DOI: 10.12659/MSM.941928  

Clinical Research  

Comparative Efficacy of Micro-Needle-Knife Therapy and Acupuncture in Acute Ankle Sprains: A Randomized Con...

Med Sci Monit In Press; DOI: 10.12659/MSM.944157  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750